KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Average (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Equity Average for 17 consecutive years, with $932.3 million as the latest value for Q1 2026.

  • For Q1 2026, Equity Average rose 278.03% year-over-year to $932.3 million; the TTM value through Mar 2026 reached $932.3 million, up 278.03%, while the annual FY2025 figure was $428.1 million, 657.62% up from the prior year.
  • Equity Average hit $932.3 million in Q1 2026 for Alnylam Pharmaceuticals, up from $511.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $932.3 million in Q1 2026 and bottomed at -$333.7 million in Q2 2023.
  • Average Equity Average over 5 years is $100.4 million, with a median of $49.7 million recorded in 2024.
  • Year-over-year, Equity Average tumbled 629.51% in 2023 and then soared 1554.27% in 2025.
  • Alnylam Pharmaceuticals' Equity Average stood at -$112.9 million in 2022, then crashed by 71.13% to -$193.3 million in 2023, then surged by 125.73% to $49.7 million in 2024, then surged by 928.81% to $511.5 million in 2025, then surged by 82.25% to $932.3 million in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $932.3 million, $511.5 million, and $242.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.